Gene polymorphisms provide a means to obtain unconfounded associations between carotenoids and various health outcomes. In the present study, we tested whether gene polymorphisms and gene scores linked to low serum carotenoid status are related to metabolic disturbance and depressive symptoms in African-American adults residing in Baltimore city, MD, using cross-sectional data from the Healthy Aging in Neighborhoods of Diversity across the Life Span study (age range 30 -64 years, n 873-994). We examined twentyfour SNP of various gene loci that were previously shown to be associated with low serum carotenoid status (SNPlcar). Gene risk scores were created: five low specific-carotenoid risk scores (LSCRS: a-carotene, b-carotene, luteinþzeaxanthin, b-cryptoxanthin and lycopene) and one low total-carotenoid risk score (LTCRS: total carotenoids). SNPlcar, LSCRS and LTCRS were entered as predictors for a number of health outcomes. These included obesity, National Cholesterol Education Program Adult Treatment Panel III metabolic syndrome and its components, elevated homeostatic model assessment of insulin resistance, C-reactive protein, hyperuricaemia and elevated depressive symptoms (EDS, Center for Epidemiologic Studies-Depression score $16). Among the key findings, SNPlcar were not associated with the main outcomes after correction for multiple testing. However, an inverse association was found between the LTCRS and HDL-cholesterol (HDL-C) dyslipidaemia. Specifically, the a-carotene and b-cryptoxanthin LSCRS were associated with a lower odds of HDL-C dyslipidaemia. However, the b-cryptoxanthin LSCRS was linked to a higher odds of EDS, with a linear doseresponse relationship. In summary, gene risk scores linked to low serum carotenoids had mixed effects on HDL-C dyslipidaemia and EDS. Further studies using larger African-American population samples are needed.
Oxidative stress, an imbalance between the production of reactive oxygen species and the ability of the cell to scavenge those species with various antioxidants, has been implicated in the pathogenesis of many chronic diseases, including type 2 diabetes mellitus, CVD, rheumatological disorders and carcinogenesis (1) . Potential beneficial effects have recently been ascribed to naturally occurring phytochemicals known as carotenoids which may reduce oxidative stress triggered by injury that characterises the pathogenesis of those chronic diseases (1) . Although the primary dietary sources of carotenoids are fruits and vegetables, they are also found in bread, eggs, beverages (e.g. carrot and tomato juices), fats and oils (2) . Among more than forty carotenoids in the human diet, only the following five carotenoids or groups of carotenoids have been shown to be consistently measurable in human serum: a-carotene, b-carotene, b-cryptoxanthin, lycopene and luteinþzeaxanthin (often combined together) (2) . Some observational studies have shown inverse associations between carotenoids and CVD (3) , type 2 diabetes (4 -8) and the metabolic syndrome (MetS) in recent national surveys (9 -11) . Moreover, in two recent studies, using the National Health and Nutrition Examination Survey (NHANES) and Invecchiare in Chianti (InCHIANTI) data, serum total carotenoid level has been shown to be consistently inversely related to depressive symptoms (12, 13) . However, the findings are inconsistent with those reported by other studies (14 -17) . It is also worth noting that obesity and its related disorders have been shown to be associated with an increased level of depressive symptoms in a number of studies (e.g. Beydoun et al. (18) , Kimura et al. (19) , Akbaraly et al. (20) ), suggesting co-morbidity between those conditions. Importantly, it is unclear whether the observed inverse relationships between serum carotenoids and the MetS and/ or depression are due to variations in carotenoid concentration or determined by other carotenoid-containing food constituents. To identify an unconfounded role of carotenoids in health and disease, surrogate measures such as genetic polymorphisms have been used in recent studies. In fact, genome-wide association studies (GWAS) and candidate gene studies have uncovered genetic polymorphisms in a number of genes that were significantly associated with serum carotenoid status. Genes carrying the specific SNP that have been commonly tested in the literature against serum carotenoid concentrations were either directly (e.g. b,b-carotene 15,15
0 -mono-oxygenase, BCMO1) or indirectly (e.g. ApoE) related to carotenoid metabolism (21 -30) . Many of these GWAS and candidate gene studies have been conducted among the individuals of European descent.
Therefore, the overall aim of the present study was to assess whether genetic polymorphisms involved in carotenoid absorption, intracellular trafficking and plasma transport are also related to a higher burden of metabolic disturbance and depressive symptoms. The present study focused on AfricanAmerican adults who were part of the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study, providing the first opportunity to examine these relationships within this racial/ethnic group. The findings could elucidate whether metabolic disturbance and/or depressive symptoms are associated with genetic polymorphisms that are in turn related to low serum carotenoid status.
Materials and methods

Database and study population
Initiated in 2004 as an ongoing prospective cohort study, the HANDLS study used area probability sampling to recruit a socio-economically diverse and representative sample of African Americans and whites (30 -64 years old) living in Baltimore, MD (31) . The HANDLS protocol was approved by the Institutional Review Board of the National Institute on Aging. The present study used cross-sectional data from the baseline HANDLS study cohort.
A total of 3720 selected subjects participated in the household survey at phase 1 (sample 1). Of these selected subjects, 2436 (65·4 %) had complete baseline phase 2 examinations (sample 2). However, our data used a subset with complete genetic data on a sample of African-American participants of the HANDLS study (n 1024, sample 3). Of these subjects, 873 had complete depressive symptom data (sample 4a) and 910-961 had complete data on metabolic outcomes (sample 5a-5i).
Genetic data
Blood samples were collected from the participants for DNA extraction, and genome-wide genotyping was completed for 1024 participants of the HANDLS study using Illumina 1M SNP coverage. For a further description of the methods used, see online supplementary methods.
Selection of SNP of interest for the present analysis was solely based on those detected in previous GWAS and candidate gene studies as highly significant predictors of serum carotenoid status (22, 28, 32) . These SNP were extracted from high-quality imputed genotypes. Most of these selected SNP are available in our database, with the exception of two b,b-carotene-9 0 ,10 0 -oxygenase (BCDO2) SNP (W80X: bovine SNP; c.196C.T: sheep SNP), which are not human SNP, and one scavenger receptor class B member 1 (SCARB1) SNP (SR-BI: intron 5) (22) . Other SNP (n 5) that were selected from one study (28) were dropped for various reasons, the most common of which was high linkage disequilibrium with the other selected SNP. None of the remaining SNP was in strong linkage disequilibrium with each other. Consequently, twenty-four distinctive SNP with reliable values were chosen. A detailed description of these selected SNP is presented in online supplementary Table S1 . SNP for lower carotenoid status, low specific-carotenoid risk score and low total-carotenoid risk score. Of the twenty-four distinctive SNP, combinations that would allow the assessment of the effect of an increasing genetic risk of lower carotenoid level on the binary measures of metabolic disturbance and depression were created. First, we examined the independent effects of each SNP allele dosage that was previously shown to be associated with a lower specific carotenoid or a group of carotenoids. To this end, from these twenty-four SNP, twenty-four genetic exposure variables were created and termed SNPlcar (SNP for lower carotenoid status). SNP dosage was coded as is or reverse coded (0,1,2 or 2,1,0) depending on whether the minor allele was associated with lower carotenoid status or vice versa (for details, see online supplementary Table S1 ).
Moreover, to assess the collective associations of SNP linked to lower levels of specific and total carotenoids with the outcomes of interest, two risk scores were created: (1) low specific-carotenoid risk score (LSCRS), by summing the SNPlcar values together that pertained to that specific carotenoid; (2) low total-carotenoid risk score (LTCRS), by summing all SNPlcar values together, reflecting low levels of all carotenoids (see online supplementary Table S2 and Fig. S1 ). In the computation of the former score, a SNPlcar was entered into a LSCRS, when previously shown to have the most significant association with a specific carotenoid (smallest P value), particularly when multiple carotenoids were affected by the same SNPlcar. We assumed that each SNPlcar was associated with the levels of specific carotenoids based on previous findings in whites, despite potential ancestral differences in African Americans, particularly in terms of linkage disequilibrium patterns (33) . Since a direct way to estimate the effect size of each SNPlcar on the levels of serum carotenoids was not available for African Americans, we did not apply SNP-specific weights from previous studies on whites to account for SNP-specific differences in the effects on carotenoid status. Thus, we simply summed the risk alleles or the combinations of risk alleles together to obtain the LSCRS and LTCRS, as was done in a previous study (34) . In each LSCRS, SNPlcar included were specific to that particular carotenoid and were not double-counted in another LSCRS.
Anthropometric indices
Body weight and standing height were measured directly. BMI (weight/(height) 2 , kg/m 2 ) was calculated for each participant. Waist circumference (cm) was measured using a tape measure starting from the hip bone and wrapping around the waist at the level of the navel. Obesity was defined as BMI $ 30 kg/m 2 , while central obesity was defined as a component of the MetS (see the 'Metabolic syndrome' section).
Metabolic outcome variables
Systolic and diastolic blood pressure. The average of the right and left sitting blood pressure values was taken to represent each of the systolic and diastolic blood pressure levels for the present analysis. Blood pressure was measured non-invasively using the brachial artery auscultation method with an aneroid manometer, a stethoscope and an inflatable cuff.
Other metabolic risk factors. Following an overnight fast, blood samples were drawn from an antecubital vein. Total cholesterol, HDL-cholesterol (HDL-C), TAG, uric acid and glucose concentrations were assessed using a spectrophotometer (Olympus 5400). Fasting serum insulin concentration was analysed with a standard immunoassay test (DPC Immulite 2000; Siemens), and C-reactive protein (CRP) concentration was analysed with an immunoturbidimetry method (Behring Nephelometer II; Siemens). Homeostatic model assessment of insulin resistance (HOMA-IR) (35) was computed with a cut-off point of 2·61, reflecting a high insulin resistance level as has been suggested elsewhere (36) . Cut-off values for hyperuricaemia were .420 mmol/l (.7 mg/dl) in men and .360 mmol/l (.6 mg/dl) in women (37) , while elevated CRP was defined as .2·11 mg/l (38) . Metabolic syndrome. Central obesity was defined by waist circumference $102 cm or 40 inches for men and $88 cm or 35 inches for women (39) . This is one of the five components in the main definition of the MetS according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) (2005) (40) . Using this definition, the MetS was positive when three or more of the following criteria screened were positive: (1) waist circumference .102 cm for men and .88 cm for women; (2) systolic blood pressure/ diastolic blood pressure $130/85 mmHg; (3) fasting glucose $5·5 mmol/l ($100 mg/dl); (4) TAG $1·7 mmol/l ($150 mg/dl); (5) HDL-C ,1·04 mmol/l (,40 mg/dl) for men and , 1·3 mmol/l (, 50 mg/dl) for women.
Assessment of depressive symptoms
Extensively trained psychometricians administered, among others, a baseline battery of cognitive and neuropsychological tests (41) that included baseline depressive symptoms using the Center for Epidemiologic Studies-Depression scale, a twentyitem, self-report symptom rating scale that emphasises the affective, depressed mood component (42) . The invariant factor structure of the Center for Epidemiologic StudiesDepression scale was recently shown using confirmatory factor analysis comparing NHANES I and HANDLS data (43) . A cut-off point of 16 was used to assess elevated depressive symptoms (EDS) in all analyses.
Covariates
Covariates considered as potential confounders included sex, age, education (below high school (grades 1 -8), high school (grades 9 -12), above high school (13þ)), poverty income ratio (below v. at or above the poverty line), smoking status (current smoker v. non-smoker), drug use (current v. past or never), and ten principal components to control for any residual effects of the population structure (see online supplementary methods).
Statistical methods
Differences in means and associations of categorical variables across 'genetic data completeness' were tested by t and x 2 tests, respectively, using Stata 13.0 (StataCorp) (44) . Then, multiple logistic regression models were conducted to test the associations of SNPlcar (entered separately in each model), five LSCRS (entered simultaneously) and one LTCRS with ten binary outcomes (obesity, MetS and five components), elevated HOMA-IR, elevated CRP, hyperuricaemia and EDS. Adjusted OR and 95 % CI were estimated. Type I error was initially set at 0·05, with regression coefficients being assessed using the Wald test. Finally, to test linear dose-response relationships, quartiles of LSCRS and LTCRS were entered into the regression models as ordinal variables, and P values for trend were computed from the Wald test. Additionally, non-linear associations were tested for each quartile compared with the lowest quartile (Q1) as the common referent category. SNPlcar analyses were corrected for multiple testing by reducing type I error to a/k (k¼24 is the number of SNP tested for each phenotype). Thus, two-sided P values were presented uncorrected, with a significance level being set at 0·05/24¼0·002.
Results
According to Table 1 , the selected participants with complete genetic data were generally older, but had a few missing data on most sociodemographic and lifestyle variables compared with those without genetic data. All LSCRS (in their continuous form) were weakly to moderately correlated (R 2 0·50 for luteinþzeaxanthin v. b-cryptoxanthin to þ 0·044 for luteinþ zeaxanthin v. lycopene). Thus, it was possible to covary these gene scores in multiple logistic regression models. the categories, and key findings included a higher intake of b-carotene and luteinþzeaxanthin among women. However, the LTCRS was not correlated with total carotenoid intake (mg/4184 kJ per d (mg/1000 kcal per d)) (R 2 0·03, P¼0·35; see online supplementary Fig. S3 ). While examining each of the twenty-four SNPlcar in a separate model as a predictor for each of the outcomes of interest, controlling for key potential confounders (see Table 2 and  online supplementary Table S3 ), a few associations emerged that were against the hypothesised direction. On the one hand, these included a putative inverse relationship between When combining SNPlcar into gene risk scores reflecting lower levels of specific carotenoids (i.e. LSCRS) and examining their associations with multiple outcomes (Table 3) , several findings emerged. First, the a-carotene LSCRS was associated with a lower odds of HDL-C dyslipidaemia (Q 4 (highest quartile) v. Q 1 (lowest quartile): OR 0·65, 95 % CI 0·44, 0·97; P¼0·037, P for trend¼0·045), with a similar pattern being observed for the b-cryptoxanthin LSCRS (Q 4 v. Q 1 : OR 0·61, 95 % CI 0·38, 0·96; P¼0·033, P for trend¼0·039). In contrast, this same LSCRS was associated with a higher odds of EDS (Q 4 v. Q 1 : OR 1·83, 95 % CI 1·07, 3·12; P¼0·026, P for trend¼0·047).
Moreover, a number of non-linear associations were also noted whereby a LSCRS was either inversely or positively associated with an outcome of interest when comparing one quartile with Q 1 , but not with others. For instance, a lower luteinþzeaxanthin gene risk score was associated with a lower odds of TAG dyslipidaemia only when comparing Q 2 with Q 1 (OR 0·51, 95 % CI 0·31, 0·83; P¼0·007). Thus, only the middle part of the distribution for lower luteinþ zeaxanthin status was linked to the reduced odds of this type of dyslipidaemia, whereas the remaining part of the distribution (Q 3 and Q 4 ) showed a comparable odds of this outcome with Q 1 . Similarly, a lower odds of EDS was found when comparing Q 2 with Q 1 of the low a-carotene gene score, but not with others. In contrast, a gene score reflecting a low lycopene level was associated with a higher risk of central obesity only when comparing Q 2 with Q 1 (OR 2·81, 95 % CI 1·09, 7·26; P¼0·033), with the association weakening with each higher quartile comparison. Importantly, the luteinþ zeaxanthin LSCRS was inversely related to the odds of having NCEP ATP III MetS, though only for Q 2 and Q 3 v. Q 1 , without a significant linear trend being observed.
As detailed in Table 4 , the associations of the LTCRS with metabolic outcomes and EDS were assessed by a series of multiple logistic regression, using quartiles of the risk score as the main predictor and testing for linear trend in the association. Among the key findings, an inverse and linear association between the LTCRS and HDL-C dyslipidaemia indicated that a gene score associated with low carotenoid status was potentially protective against this outcome (Q 4 v. Q 1 : OR 0·67, 95 % CI 0·45, 0·99; P¼0·046, P for trend¼0·046). Similarly, a non-linear association was found for elevated CRP (Q 2 v. Q 1 : OR 0·63, 95 % CI 0·43, 0·91; P¼0·015).
Discussion
In the present study, we examined the associations of gene polymorphisms related to low carotenoid status with various metabolic outcomes and EDS in an urban, socio-economically diverse sample of African-American adults. None of the key findings for SNP analyses survived correction for multiple testing. However, an inverse association was found between the LTCRS and HDL-C dyslipidaemia. The b-cryptoxanthin LSCRS was associated with a lower odds of HDL-C dyslipidaemia, but a higher odds of EDS.
Previous studies that examined SNP used in our SNPlcar focused on dyslipidaemia, type 2 diabetes, obesity and the MetS. Particularly, SNPlcar 1(ABCG5,rs6720173:C/G,luteinþ zeaxanthin) (21, 22) has been found to be unrelated to HDL-C dyslipidaemia or other lipids based on a study of Puerto Rican adults, while other associations were found for various other SNP studied on that gene locus (45) . The main function of ABCG5 (ATP-binding cassette, subfamily G, member 5) is to translocate various hydrophobic substrates including carotenoids and cholesterol across extra-and intracellular membranes (21) . Moreover, only a few studies directly examined the associations of SNPlcar 2(ApoB-516,b-carotene) (22, 23) with lipid profile and other metabolic disturbances. In one study (46) , while another ApoB SNP (rs676210) has been reported to be associated with the lowering of TAG, SNPlcar 2 (rs934197:T/C) has not been found to be associated, a finding replicated by at least one other study (47) . However, two recent studies have detected an association of the 'T' allele dosage of that SNP with a higher postprandial TAG level (48) and increased insulin resistance (49) . In the present study, before correction for multiple testing (see Table 2 and online supplementary Table S2 ), the ApoB-516 'C' allele dosage (SNPlcar 2(ApoB) ) yielded an inverse association with the MetS (OR 0·72, 95 % CI 0·52, 1·00; P¼0·048) and elevated CRP (OR 0·70, 95 % CI 0·51, 0·95; P¼ 0·022), which is consistent with previous studies. However, this finding was against the hypothesised direction that genetic polymorphisms linked to lower carotenoid status would be related to a higher odds of metabolic outcomes and EDS. ApoB is essential for the assembly and secretion of chylomicra and/or VLDL in the small intestine and the liver. It is also the main apo of LDL-C, a major carrier of carotenoids and TAG-rich lipoproteins (50) . The main function of ApoA-IV is lipid absorption and modifying lipoprotein size (51) . Although no associations were detected in the present study with SNPlcar 3 (ApoA-IV, rs675:A/T), previously linked to lower serum lycopene (22, 23) , other studies have shown that this SNP was associated with the ability of fenofibrate to lower TAG levels among non-MetS patients (52) . Moreover, in that same study (52) , one of the ApoE SNP included in SNPlcar 4 (rs429358:C/T) was associated with increased LDL-C levels after fenofibrate treatment in the MetS group. ApoE2 has been reported to have established atheroprotective properties based on previous studies (e.g. Morabia et al. (53) ). However, we did not detect significant associations between SNPlcar 4(ApoE) and any of the outcomes studied.
BCMO1 and BCDO2 are involved in symmetric and asymmetric carotenoid cleavage, respectively, and convert b-carotene and apocarotenals to retinal, thus influencing the circulatory levels of carotenoids (54) . For two of the most highly studied SNP in the BCMO1 gene (SNPlcar 5 : rs6564851:G/T and SNPlcar 6 : rs6564851:T/G), with SNPlcar 5(BCMO1,luteinþ zeaxanthin) and SNPlcar 6(BCMO1,b-cryptoxanthin) , no relationship was observed with metabolic outcomes or EDS, in accordance with a meta-analysis suggesting that the loss of BCMO1 function was unrelated to a higher risk of type 2 diabetes (55) . Moreover, in a recent French-Canadian study (56) , it has been demonstrated that SNPlcar 7(BCMO1,b-carotene) and SNPlcar 13(BCMO1,b-carotene) (28) had no association with a lower HDL-C level. No other SNPlcar on the BCMO1 gene locus have previously been studied in relation to metabolic disturbance or depressive symptoms. In the present study, although none of the associations remained significant after correction for multiple testing, among the notable associations before that correction, SNPlcar 14(BCMO1,b-cryptoxanthin) (28) was associated with a higher odds of EDS (OR 2·05, 95 % CI 1·27, 3·31; P¼0·003; Table 2 ). Other associations detected were either in the expected direction (SNPlcar 12(BCMO1,a-carotene) and central obesity; SNPlcar 14(BCMO1,b-cryptoxanthin) and SNPlcar 16(BCMO1,b-carotene) with hypertension) or against the hypothesised direction (SNPlcar 17(BCMO1,b-carotene) and obesity; SNPlcar 10(BCMO1,b-cryptoxanthin) and hypertension). Thus, further larger studies are needed to reconcile those inconsistent findings within that gene locus. SNPlcar 19(CD36,luteinþ zeaxanthin) (thrombospondin receptor gene (rs13230419)) has been shown to increase the odds of the MetS by 29-40 % in the African-American population (57) .
CD36 codes for a membrane protein that facilitates the uptake and utilisation of fatty acids in key metabolic tissues. The present study found a similar putative effect, though there was only a significant or marginally significant association with the MetS before correction for multiple testing Table S1 ). Covariates entered as potential confounders included sex, age, poverty income ratio (,125 v. $125 %), education (below high school, high school or above high school), marital status (current, former, never or missing), smoking status (current, former, never or missing), drug use (current, past, never or missing) and ten principal components to adjust for population structure. 1  0·93  0·63, 1·37  0·70  0·93  0·63, 1·36  0·70  0·87  0·59, 1·28  0·49  0·60  b-Carotene  1  0·82  0·55, 1·23  0·34  1·06  0·72, 1·56  0·77  0·88  0·59, 1·32  0·55  0·92  Luteinþzeaxanthin  1  0·88  0·59, 1·31  0·53  0·92  0·61, 1·41  0·72  0·85  0·55, 1·31  0·46  0·59  b-Cryptoxanthin  1  1·00  0·66, 1·47  0·96  0·80  0·53, 1·22  0·30  0·90  0·58, 1·40  0·65  0·44  Lycopene  1 0·87, 1·95  0·21  1·13  0·76, 1·69  0·55  1·21  0·80, 1·83  0·37  0·61  Luteinþzeaxanthin  1  0·79  0·53, 1·19  0·26  0·68  0·44, 1·04  0·08  0·84  0·54, 1·31  0·45  0·30  b-Cryptoxanthin  1  1·06  0·71, 1·59  0·78  0·96  0·62, 1·47  0·86  0·74  0·42, 1·33  0·32  0·97  Lycopene  1  0·90  0·39, 2·09  0·82  0·96  0·54, 1·71  0·90  0·75  0·42, 1·33  0·32  0·12  Dyslipidaemia, HDL-C (n 989) a- Carotene  1  0·71  0·47, 1·06  0·09  0·68  0·45, 1·01  0·06  0·65  0·44, 0·97  0·037  0·045  b-Carotene  1  0·91  0·60, 1·39  0·68  1·23  0·82, 1·83  0·32  1·02  0·67, 1·54  0·93  0·51  Luteinþzeaxanthin  1  0·73  0·48, 1·10  0·13  0·65  0·42, 1·00  0·05  0·80  0·51, 1·25  0·32  0·34  b-Cryptoxanthin  1  0·82  0·54, 1·24  0·34  0·70  0·46, 1·07  0·10  0·61  0·38, 0·96  0·033  0·039  Lycopene  1  1·06  0·45, 2·48  0·89  0·89  0·50, 1·60  0·70  0·75  0·42, 1·34  0·33  0·14  Dyslipidaemia, TAG (n 989) a- Carotene  1  1·21  0·76, 1·91  0·43  0·69  0·42, 1·15  0·16  1·01  0·63, 1·62  0·96  0·48  b-Carotene  1  1·02  0·62, 1·69  0·93  1·06  0·65, 1·73  0·82  1·11  0·68, 1·83  0·67  0·71  Luteinþzeaxanthin  1  0·51  0·31, 0·83  0·007  0·68  0·41, 1·12  0·13  0·80  0·47, 1·35  0·40  0·39  b-Cryptoxanthin  1  0·78  0·47, 1·28  0·33  0·95  0·57, 1·57  0·83  0·83  0·48, 1·44  0·51  0·63  Lycopene  1  2·02  0·72, 5·65  0·18  1·80  0·84, 3·89  0·13  1·26  0·59, 2·75  0·55  0·52  Hyperglycaemia (n 989) a- Carotene  1  0·83  0·55, 1·24  0·35  0·85  0·57, 1·27  0·43  1·06  0·71, 1·57  0·78  0·84  b-Carotene  1  1·22  0·82, 1·83  0·33  1·13  0·76, 1·69  0·61  0·94  0·62, 1·42  0·76  0·68  Luteinþzeaxanthin  1  0·80  0·54, 1·19  0·28  0·65  0·42, 1·00  0·05  0·88  0·56, 1·37  0·56  0·39  b-Cryptoxanthin  1  0·84  0·56, 1·26  0·39  0·84  0·55, 1·28  0·43  0·83  0·53, 1·30  0·42  0·61  Lycopene  1  2·16  0·91, 5·13  0·08  1·65  0·87, 3·06  0·12  1·39  0·75, 2·57  0·30  0·92  Elevated HOMA-IR (n 986) a-Carotene
a- Carotene  1  0·98  0·67, 1·43  0·91  0·84  0·57, 1·23  0·37  1·06  0·72, 1·55  0·76  0·92  b-Carotene  1  1·27  0·86, 1·87  0·23  1·33  0·91, 1·95  0·14  0·92  0·62, 1·36  0·67  0·72  Luteinþzeaxanthin  1  0·95  0·65, 1·41  0·81  0·99  0·67, 1·50  0·97  0·81  0·53, 1·25  0·35  0·35  b-Cryptoxanthin  1  1·00  0·68, 1·48  0·99  1·02  0·68, 1·53  0·92  0·94  0·61, 1·44  0·76  0·84  Lycopene  1  0·97  0·42, 2·25  0·94  0·78  0·44, 1·36  0·38  0·69  0·39, 1·20  0·19  0·12  Hyperuricaemia (n 989) a- Carotene  1  0·64  0·41, 0·98  0·040  0·66  0·43, 1·02  0·06  0·89  0·58, 1·34  0·57  0·51  b-Carotene  1  1·11  0·71, 1·74  0·63  1·24  0·80, 1·93  0·33  1·12  0·71, 1·77  0·61  0·46  Luteinþzeaxanthin  1  0·79  0·51, 1·23  0·30  1·01  0·64, 1·59  0·98  0·91  0·56, 1·48  0·72  0·89  b-Cryptoxanthin  1  0·75  0·48, 1·17  0·20  0·85  0·54, 1·33  0·47  0·77  0·47, 1·25  0·29  0·44  Lycopene  1  1·35  0·53, 3·44  0·53  1·35  0·71, 2·56  0·36  1·02  0·53, 1·94  0·96 1  0·61  0·38, 0·96  0·034  0·80  0·50, 1·23  0·30  0·71  0·46, 1·11  0·14  0·31  b-Carotene  1  1·14  0·71, 1·82  0·58  0·98  0·62, 1·54  0·92  0·93  0·58, 1·48  0·76  0·65  Luteinþzeaxanthin  1  0·98  0·61, 1·56  0·89  1·04  0·63, 1·72  0·89  1·52  0·92, 2·54  0·10  0·11 (OR 1·41, 95 % CI 0·99, 2·00; P¼ 0·06) and TAG dyslipidaemia (OR 0·66, 95 % CI 0·46, 0·94; P¼ 0·021). In contrast, the present study did not find any significant associations with SNPlcar 18 . SNPlcar 18(CD36,low luteinþ zeaxanthin with more 'A' alleles) (22, 58) was related to the MetS in one previous case -control study of Egyptian adults, with the 'G' allele being more prevalent in cases (n 100) than in controls (n 100) (59) . A similar finding was observed in another study of 317 African-American adults, in which the 'A' allele of CD36 (rs1761667:A/G) was associated with greater perceived creaminess regardless of the fat content of salad dressings (P, 0·01) and a higher mean acceptance of added fats and oils (P¼0·02) without a significant association with the obesity phenotype (60) . Hepatic lipase (LIPC) hydrolyses TAG and phospholipids from HDL, intermediate-density lipoproteins and LDL, transforming them into smaller and denser particles, and promoting the cellular uptake of HDL-C (61) . For the two LIPC gene SNPlcar (both rs1800588:T/C), SNPlcar 20 (TT v. others) has been previously shown to be associated with a low a-carotene level, while SNPlcar 21 (C allele) has been linked to a low b-carotene level (22, 61) . A study conducted among a large cohort of Chinese adults (n 4194) has shown that the 'T' allele was linked to a higher HDL-C level than the 'C' allele (P,0·0001) (62) . The same pattern has been found in a large cohort study of Caucasian adults (n 4662), with the 'C' allele being associated with HDL-C dyslipidaemia (P, 0·0001) (63) . The present study failed to detect an association between LIPC SNPlcar and various outcomes of interest.
Fatty acid-binding protein 2 (FABP2)-related SNPlcar 22 (rs1799883:A/G, GG v. others) was previously associated with a lower serum lycopene level (22, 29) . In a study of 315 elderly subjects with the MetS who were of European descent, the 'G' allele was linked to lower TAG and higher HDL-C levels (P,0·05), indicative of lower risk for dyslipidaemia of both types (64) . There were no notable associations between this polymorphism and any of the outcomes of interest investigated in the present study. FABP2 is an intracellular protein expressed only in the intestine, which is involved in the absorption and intracellular transport of dietary long-chain fatty acids and carotenoids to their specific metabolic targets (61) . For lipoprotein lipase (LPL)-related SNPlcar 23 (rs328:G/C; GG v. CC, mainly low a-carotene level (22, 30) ), two previous studies conducted among Caucasian adults also indicated that the 'C' allele was consistently linked to HDL-C dyslipidaemia (63, 65) , with one of them observing an additional link to TAG dyslipidaemia (65) . However, a recent meta-analysis showed only a modest relationship between rs328:G/C and both types of dyslipidaemia (66) . Before correction for multiple 1  1·68  1·05, 2·70  0·031  1·31  0·80, 2·14  0·28  1·83  1·07, 3·12  0·026  0·047  Lycopene  1  1·50  0·60, 3·75  0·39  0·80  0·41, 1·57  0·52  0·85  0·44, 1·66  0·64  0·37 HDL-C, HDL-cholesterol; CES-D, Center for Epidemiologic Studies-Depression. * All LSCRS were entered in the same multiple logistic regression model (as quartiles, with the first quartile being the reference category) as main predictors, to assess their net association with each of the metabolic outcomes and with EDS. Covariates entered as potential confounders were sex, age, poverty income ratio (,125 v. $ 125 %), education (below high school, high school or above high school), marital status (current, former, never or missing), smoking status (current, former, never or missing), drug use (current, past, never or missing) and ten principal components to adjust for population structure. 0·58, 1·26  0·44  1·11  0·76, 1·63  0·59  0·80  0·54, 1·17  0·25  0·50  Central obesity  1  0·85  0·56, 1·30  0·45  1·01  0·66, 1·55  0·96  0·83  0·54, 1·27  0·38  0·56  NCEP ATP III MetS  1  0·87  0·57, 1·32  0·51  0·71  0·45, 1·09  0·12  0·68  0·44, 1·05  0·08  0·05  Elevated blood pressure  1  0·86  0·59, 1·27  0·46  0·70  0·48, 1·04  0·08  0·88  0·59, 1·30  0·52  0·34  Dyslipidaemia, HDL-C  1  0·80  0·54, 1·19  0·28  0·76  0·51, 1·12  0·17  0·67  0·45, 0·99  0·046  0·046  Dyslipidaemia, TAG  1  1·28  0·81, 2·02  0·29  0·91  0·56, 1·46  0·69  0·79  0·48, 1·29  0·35  0·18  Hyperglycaemia  1  0·93  0·63, 1·38  0·71  1·14  0·76, 1·69  0·50  0·93  0·62, 1·39  0·73  0·99  Elevated HOMA-IR  1  0·90  0·61, 1·32  0·59  1·25  0·86, 1·81  0·24  0·82  0·56, 1·22  0·34  0·73  Elevated CRP  1  0·63  0·43, 0·91  0·015  0·75  0·52, 1·10  0·14  0·79  0·54, 1·16  0·23  0·41  Hyperuricaemia  1  1·17  0·77, 1·78  0·45  0·92  0·60, 1·42  0·71  0·92  0·60, 1·43  0·72  0·48  EDS, CES-D score $ 16  1  1·10  0·71, 1·74  0·65  1·25  0·80, 1·97  0·33  1·16  0·74, 1·82  0·52  0·45 HDL-C, HDL-cholesterol; CES-D, Center for Epidemiologic Studies-Depression. * The LTCRS was entered in the multiple logistic regression model (as quartiles, with the first quartile being the reference category) as main predictors, to assess their net association with each of the metabolic outcomes and with EDS. Covariates entered as potential confounders were sex, age, poverty income ratio (, 125 v. $125 %), education (below high school, high school or above high school), marital status (current, former, never or missing), smoking status (current, former, never or missing), drug use (current, past, never or missing) and ten principal components to adjust for population structure.
testing, the present study was indicative of a consistent relationship in which the 'G' allele was associated with a lower odds of elevated HOMA-IR (OR 0·66, 95 % CI 0·44, 0·98; P¼ 0·037; see online supplementary Table S3 ). However, this SNPlcar was not found to be associated with any type of dyslipidaemia in the present study. LPL catalyses the hydrolysis of the TAG component of circulating chylomicrons and VLDL, in tissues other than the liver, and indirectly affects the concentration of carotenoids (30) . SCARB1 SNPlcar 24 (SR-BI exon 1, rs61932577:A/G; GG v. others), previously linked to a lower level of b-cryptoxanthin (22, 23) , was also studied in relation to lipid profiles among adults. SRBI has been shown to play a role in the metabolism of ApoB-containing lipoproteins in animal models and human subjects. In fact, SRBI constitutes a back-up pathway to the usual LDL receptor-mediated pathways for the catabolism of these lipoproteins. This is particularly relevant to adults with high ApoB-containing lipoproteins, commonly occurring in patients with familial hypercholesterolaemia (67) . Before correction for multiple testing, the present study found that SNPlcar 24(SCARB1) (i.e. higher 'G' allele dosage) was linked to a higher odds of obesity, but no association was found with HDL-C or TAG dyslipidaemia. The associations of SCARB1 with HDL-C and TAG dyslipidaemia were investigated previously, with a higher dosage of the 'A' allele being related to higher HDL-C and lower LDL-C values in men, but not in women (68) . This finding was replicated in a large study of US Caucasians (Framingham study: 2463 non-diabetic and 187 diabetic), in which diabetic subjects with the less common allele (allele A) had lower lipid concentrations, particularly LDL-C (69) . Those two studies had a consistent pattern of association found in the present study, though with different outcomes. However, two other studies found no associations of this SNPlcar with various lipid parameters (53, 70) . Inconsistent with the pattern of findings from the present study and those of others, a study of seventy-seven subjects who were heterozygous for familial hypercholesterolaemia has found that the 'A' allele dosage of this SNP was associated with higher TAG (67) . To our knowledge, the present study is the first to systematically examine genetic polymorphisms previously shown to be associated with the lower levels of serum carotenoids in relation to metabolic disturbance and depressive symptoms in an urban population of African-American adults, and to construct gene scores for that purpose. Despite its strengths, some limitations include a statistical power-limiting small sample size. Moreover, most GWAS yielding our SNPlcar short list came from studies of subjects of European ancestry. Finally, data on serum carotenoid concentrations were lacking, which prevented the direct assessment of SNPlcar associations with respective carotenoids and comparisons with previous studies of European ancestry subjects. Additionally, such data availability would have allowed the use of gene score weights depending on effect sizes of each SNPlcar on various carotenoids. Finally, in few gene loci included in of gene score computations, a SNP was related to multiple carotenoids, specifically BCMO1. However, to bypass this issue, the gene scores were made mutually exclusive by including only the most significant carotenoid for each of the carotenoid-specific gene score.
In conclusion, gene polymorphisms linked to low serum carotenoid status had mixed effects on metabolic disturbance and depression. Specifically, our findings do not support that gene polymorphisms associated with low carotenoid status will necessarily lead to a poorer metabolic and depressive symptom outcome. In fact, in most cases, the opposite trend was found, with the possible exception of the b-cryptoxanthin risk score and EDS. Therefore, there is a major discrepancy between what was found in studies linking serum carotenoids to metabolic disturbance and depressive symptoms and the present study that used gene polymorphisms linked to low carotenoid status as the main exposure. It is possible that different carotenoids may interact either synergistically or antagonistically with each other to affect these outcomes. Thus, similar studies on larger African-American samples are needed to test gene-gene (epistasis) interactions between these carotenoid-related gene polymorphisms.
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